🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In Australia, among 95,272 people with #hepC receiving DAA therapy by end of 2021, 7% were retreated. 52% of retreatment was for reinfection; 48% for treatment failure. Post-treatment #hepC care is essential for people at risk of reinfection. 📕Read more: doi.org/10.1016/j.jhep…

Applications open now for the David Cooper Scholarship! 🔬 4yr PhD for candidates in infectious diseases 📈 career development fund, up to $10k/year 🧑‍💼 research training + career development program 🤝 6m internship with academic unit/industry partner kirby.unsw.edu.au/news/apply-now…

Are you an ECR at UNSW Medicine & Health? Med ECAN have limited paid spots for Stats Central short courses in 2023! Email your CV and Z-ID to [email protected] by 1st March for a spot in the upcoming Sample Size and Power Calculations course analytical.unsw.edu.au/facilities/sta…

Proud of our team for publishing 2 systematic reviews in the Lancet Glob Health on the prevalence of injecting drug use and the coverage of harm reduction interventions for PWID thelancet.com/journals/langl… thelancet.com/journals/langl…

WEBINAR: Hear from authors of top-ranked research papers from #INHSUPrisons2022 Bibliography 📣 Speakers Jack Stone, Timothy Papaluca @StVincentsMelb, Joanne Carson Kirby Institute, UNSW 📣 Moderators Nadine Kronfli McGill University Julia The Hepatitis C Trust inhsu.org/events/inhsu-p…

Among people who inject drugs globally, an estimated 15% are living with #HIV and 39% are living with #HCV, Jason Grebely presented in the Harm Reduction International #HR23 Kirby Institute, UNSW NDARC, UNSW

New global data on #HCV and #HIV testing/treatment among PWID presented by Behzad Hajari Kirby Institute, UNSW from study in collaboration with NDARC, UNSW at #HR23 Harm Reduction International. Demonstrates continued low uptake of HCV/HIV testing/treatment globally. Interventions needed to enhance uptake.

Latest global estimates on HIV, HCV Ab/RNA testing coverage among people who inject drugs presented by ⁦⁦Behzad Hajari⁩ #HR23

Join us this coming Tuesday to hear the fascinating history of hepatitis A, B and C from Dr Michelle Bootcov Michelle Bootcov 📅 1pm AEST, Tue 2 May | In-person and online | Free 🎫 Registrations essential: how-to-know-a-virus.eventbrite.com.au/?aff=SM 🗣️ Event page: kirby.unsw.edu.au/event/dr-miche…

Our study Kirby Institute, UNSW UNSW Medicine & Health demonstrated that 9% of people with #HCV in 🇦🇺 discontinued therapy (6% in 2016 to 15% in 2021). This📈corresponds to expanding therapy to more marginalized people & highlights needs for access to adherence support & retreatment. @gregdore2

🌟 We're proud to present our 2022 Annual Report. 🌟 In 2022, our team of passionate researchers contributed significant, impactful discoveries to improve health and save lives. Read the report now: kirby.unsw.edu.au/report/annual-…

Join Behzad Hajari at #INHSU2023 for a presentation on "Global, regional, and country-level coverage of testing and treatment for #HIV and #HCV infection among people who inject drugs: a systematic review." Plenary abstract speakers now announced: inhsu.org/inhsu-2023/pro…

Our new paper - open access! Views of key informants on evidence and targets to achieve hepatitis C elimination goals in Australia Dr Lise Lafferty Joanne Bryant (she/her) Jake Rance doi.org/10.1111/jvh.13…

Globally, only 49% of people who inject drugs were tested for HIV & 47% for hepatitis C. Study by Kirby Institute, UNSW NDARC, UNSW in The Lancet Global Health showed low testing & treatment uptake in this population in most countries. Strategies to improve access are required: doi.org/10.1016/S2214-…

Amazing work - massive congrats Hep B PAST team 🎉🎉🎉

Join #INHSUEMCR & CHERISH for a webinar with Ali Jalali, PhD & Shashi Kapadia. Learn: ➡️Purpose & approach to economic evaluations ➡️Best practices for determining intervention costs ➡️ Approaches to estimating cost-effectiveness Register: inhsu.org/events/webinar…

Great to see this paper in press The Lancet Gastroenterology & Hepatology Amazing leadership from Alison Marshall Kirby Institute, UNSW to pull together this network. Thanks to our global collaborators, including John Ward & Lindsey Hiebert-Suwondo Coalition for Global Hepatitis Elimination, Jeffrey V. Lazarus, Andrew Scheibe, & Peter Vickerman

Interested in #HCV elimination, and in particular the role of reinfection? read more about it in this paper! Very happy to have been able to contribute to this work with such amazing colleagues 🤓

Can you help us? We are looking for data for our global #prison review examining #bloodborne virus infections, drug use and harm reduction services among #incarcerated people. 📥 Please get in touch with us at [email protected]

1/2 Recognise the achievements and uplift an emerging leader working in the #BBV, #STI, or sexual and reproductive health sector with the 2024 Levinia Crooks Emerging Leader Award. Nominate an early-to-mid career professional now: buff.ly/3X5vusR